Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — Q1 2026 Earnings Presentation
19 slides from Onward Medical's earnings presentation, May 26, 2026
Slide 1: Investor Webcast Q1 2026 Business Update
Investor Webcast Q1 2026 Business Update May 26, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be “forward-looking statements”. These forward- looking statements may be identified by the use of forward-looking terminology, includi
Slide 3: Speaking Today
Speaking Today Dave Marver Sean Sciara Ali Kiboro Chief Executive Officer Chief Commercial Officer Chief Financial Officer May 2026 Webcast 3
Slide 4: Q1 2026 Business Updates
Q1 2026 Business Updates
Slide 5: Q1 & YTD Highlights
Strong commercial momentum and Q1 & YTD achievement of key clinical milestones Highlights Commercial traction €2.0M in revenue in Q1 2026 and 70 ARCEX Systems supplied for use in clinics and homes; ARCEX Systems available in over 100 clinics across US and Europe by end of Q1 Clinical milestones o Fi
Slide 6: ARC EX
ARCEX May 2026 Webcast 6
Slide 7: ARC EX Commercial Uptake
Steady growth in ARCEX uptake ARCEX Commercial with 70 units supplied in Q1 2026 Uptake # of units supplied 47 units 70 units > 100 clinics >80 US clinics penetrated penetrated globally 40 units >50 US clinics penetrated 20 units 10 units Q1 Q2 Q3 Q4 Q1 2025 2026 Limited US clinic Broad US clinic US
Slide 8: ARC EX Clinic Footprint
As of 31 March 2026 100+ clinics equipped with ARCEX ARCEX Clinic in US and Europe Footprint Widespread US adoption Growing European footprint May 2026 Webcast 8
Slide 9: Europe Sales Update
As of 31 March 2026 Ramping up operations in Europe Europe Sales Update via direct and indirect channels Direct market Indirect market o Direct sales team now active and covering 6 markets o Onboarded initial distribution partners in indirect markets o Hosted distributor workshop in April 2026, intr
Slide 10: Empower BP Update
As of 26 May 2026 Empower BP continues to advance, Empower BP Update with first implant completed in Q1 2026 and 12 sites now activated First patient implanted 12 US sites activated Note: Map includes active centers and selected centers pending activation. For details, visit onwd.com/empower-bp May
Slide 11: ARC IM Mobility Feasibility Study
Continued progress on SCI mobility with ARCIM Mobility the start of EIGER feasibility study Feasibility Study Starting EIGER study with the objective to clinically validate commercially viable inclusion criteria and workflows Enrolling 12 patients – 6 with chronic and 6 with sub-acute SCI May 2026 W
Slide 12: Financing Update
Successfully raised over EUR 40 Financing Update million in equity capital to fuel growth o Supported by EUR 25M investment from EQT Life Sciences o Strong demand from existing and new high-quality, long-only and sector specialist investors o Cash runway now extends into Q1 2028 May 2026 Webcast 12
Slide 13: Q1 2026 Results
Q1 2026 Results
Slide 14: Q1 2026 Cash Update
Strengthened balance sheet to €89.8M Q1 2026 net cash as of 30 April 2026 and generated €2.0M in revenues in Q1 2026 Cash Update Burn Ending Current Cash Revenue €14.7M used Balance Q1 Balance3 €2.0M in Q1 20261 during Q1 2026 €53.4M net cash2 €89.8M net cash as of 31 Mar 2026 as of 30 Apr 2026 1 Re
Slide 15: 2026 Outlook
2026 Outlook
Slide 16: Upcoming Milestones and News Flow
Several important catalysts expected in the next 12 months Upcoming Milestones ARCEX ARCIM ARCBCI and News Flow ARCEX ARCEX ARCEX ARCEX First commercial clinic First commercial home First commercial home First commercial clinic sale (EU) use sale (US) use sale (EU) sale (ROW) Hand sensation & Hand s
Slide 17: Q&A
Q&A
Slide 18: Thank you!
Thank you! 18
Slide 19: Slide 19